Cabotegravir Injectable Depot

The cabotegravir injectable depot developed by CONRAD is a high priority, long-acting, low-cost, biodegradable silica hydrogel injectable depot product that provides a similar active pharmaceutical ingredients dose to the clinically tested cabotegravir long-acting nanosuspension in a smaller volume (~1 mL), subcutaneous (less painful), lasting 2-3-fold longer (4-6 months duration), with potential for a shorter pharmacokinetics tail. A cabotegravir depot product has the value added of a potential fast-track regulatory strategy based on existing efficacy and pharmacokinetics/pharmacodynamic benchmarks. Lead formulations will be optimized and advanced through pre-clinical and investigational new drug enabling studies supporting clinical development through staggered Phase 1 trials.